8-K: Novartis Completes Avidity Biosciences Acquisition
Merger Completion and Spin-off Announcement
Novartis AG has completed its acquisition of Avidity Biosciences, Inc. for $72.00 per share in cash, following a pre-merger spin-off of Avidity's early-stage cardiology programs into Atrium Therapeutics, Inc.
Summary
- Avidity Biosciences, Inc. (Avidity) has been acquired by Novartis AG (Novartis) through its subsidiary, Ajax Acquisition Sub, Inc. (Merger Sub), with Avidity becoming an indirect wholly owned subsidiary of Novartis.
- At the effective time of the merger, each share of Avidity common stock was cancelled and converted into the right to receive $72.00 in cash, without interest and subject to tax withholdings.
- Outstanding Company Stock Options with an exercise price less than the Merger Consideration were fully vested and converted into a cash payment equal to the difference between the Merger Consideration and the exercise price, multiplied by the number of shares.
- Outstanding Company Restricted Stock Units (RSUs), excluding New Hire RSUs, were fully vested and converted into a cash payment equal to the Merger Consideration multiplied by the number of shares.
- New Hire RSUs were converted into cash awards subject to service-based vesting.
- Prior to the merger, Avidity completed a separation and distribution, spinning off its early-stage precision cardiology programs (including AOC 1086 and AOC 1072, and collaborations with Bristol-Myers Squibb Company and Eli Lilly and Company) into a new independent publicly held company, Atrium Therapeutics, Inc. (formerly Bryce Therapeutics, Inc.).
- Avidity distributed one share of Atrium Therapeutics, Inc. common stock for every ten shares of Avidity common stock held as of the record date of February 12, 2026.
- Avidity's common stock was halted from trading on Nasdaq at 8:00 p.m. Eastern time on February 26, 2026, and will be suspended from trading on Nasdaq on March 2, 2026, with subsequent delisting and deregistration planned.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a positive development for Avidity shareholders who received a premium cash payout. The strategic spin-off also creates a new independent entity, potentially maximizing value for the early-stage assets.
Positives
- Avidity Biosciences shareholders received a significant cash payment of $72.00 per share, representing a premium for their investment.
- The spin-off of early-stage precision cardiology programs into Atrium Therapeutics, Inc. creates a new independent publicly traded company, potentially allowing these assets to be developed with focused resources and attracting specialized investment.
- Equity award holders (stock options and RSUs) received cash or cash awards, providing liquidity and value realization.
Negatives
- Avidity Biosciences, Inc. ceases to exist as an independent publicly traded entity, and its common stock will be delisted from Nasdaq.
- Existing Avidity shareholders no longer hold equity in the acquired company, transitioning to cash and shares in the new spun-off entity.
Future Outlook
Avidity Biosciences, Inc. will cease to be a publicly traded company. Following the effectiveness of Form 25 for delisting and deregistration, the company intends to file Form 15 to terminate its registration under the Exchange Act and suspend its reporting obligations.
Industry Context
StockSavvy.ai notes this transaction represents a strategic consolidation within the biotechnology sector, where a major pharmaceutical company like Novartis acquires a specialized biotech firm to integrate its therapeutic pipeline. The concurrent spin-off of early-stage cardiology assets into Atrium Therapeutics, Inc. allows for a focused development path for those programs, potentially appealing to investors interested in specific therapeutic areas, while the acquired entity's programs are integrated into Novartis's broader portfolio. This strategy can unlock value by separating distinct business units with different risk profiles and investment horizons.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Carsten Boess | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Sarah Boyce | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Troy Wilson, Ph.D., J.D. | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Arthur A. Levin, Ph.D. | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Simona Skerjanec | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Tamar Thompson | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Noreen Henig, M.D. | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Edward M. Kaye, M.D. | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Jean Kim | 2026-02-27 | Resigned in connection with the merger. | |
| Director | Jaime Huertas | 2026-02-27 | Appointed as director of the Surviving Corporation (from Merger Sub). | |
| Director | Eduard Marti | 2026-02-27 | Appointed as director of the Surviving Corporation (from Merger Sub). | |
| Executive Officer | Sarah Boyce | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Charles Calderaro III | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | W. Michael Flanagan, Ph.D. | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Katleen Gallagher | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Steven Hughes, M.D. | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Michael F. MacLean | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Teresa McCarthy | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | John B. Moriarty, Jr, J.D. | 2026-02-27 | Removed from position in connection with the merger. | |
| Executive Officer | Eric Mosbrooker | 2026-02-27 | Removed from position in connection with the merger. | |
| President | John McKenna | 2026-02-27 | Appointed as President of the Surviving Corporation (from Merger Sub). | |
| Treasurer | Eduard Marti | 2026-02-27 | Appointed as Treasurer of the Surviving Corporation (from Merger Sub). | |
| Secretary | Jamie Huertas | 2026-02-27 | Appointed as Secretary of the Surviving Corporation (from Merger Sub). |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | The Company's certificate of incorporation was amended and restated in its entirety to conform to the requirements of a wholly owned subsidiary. | 2026-02-27 | Reflects the company's new status as a wholly owned subsidiary, likely reducing shareholder rights and board independence. |
| Bylaws Amendment | The Company's bylaws were amended and restated in their entirety to conform to the bylaws of Merger Sub, with name changes to reflect the Surviving Corporation. | 2026-02-27 | Aligns corporate governance with the parent company's structure and operational preferences for its subsidiaries. |
| Agreement Termination | The Stock Plans and the Employee Stock Purchase Plan (ESPP) were terminated. | 2026-02-27 | Ends equity compensation programs for former public company employees, consistent with becoming a private subsidiary. |
| Agreement Termination | The Sales Agreement, dated August 9, 2024, with TD Securities (USA) LLC was terminated. | 2026-02-27 | Ends the at-the-market equity offering program, as the company is no longer publicly traded. |
Stakeholder Impact
- Shareholders: Received a cash payment of $72.00 per share for their Avidity stock and shares in the newly spun-off Atrium Therapeutics, Inc.
- Employees: Former Avidity employees' equity awards were converted to cash or cash awards. Significant changes in the board of directors and executive officers occurred.
- Customers/Partners: Collaboration agreements related to early-stage precision cardiology programs (e.g., with Bristol-Myers Squibb and Eli Lilly) were transferred to Atrium Therapeutics, Inc. as part of the spin-off.
Next Steps
- Nasdaq will file a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister Avidity Common Stock.
- Avidity intends to file a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act to terminate registration and suspend reporting obligations.
Key Dates
| Date | Description |
|---|---|
| 2025-10-25 | Date of the Merger Agreement and Separation and Distribution Agreement. |
| 2025-10-27 | Previous Current Report on Form 8-K filed with the SEC regarding the Merger Agreement. |
| 2025-12-08 | Bryce Therapeutics, Inc. changed its name to Atrium Therapeutics, Inc. |
| 2026-02-12 | Distribution Record Date for the pro rata distribution of SpinCo Common Stock. |
| 2026-02-26 | Separation and Distribution of SpinCo Common Stock completed; Trading halt on Avidity Common Stock effective at 8:00 p.m. Eastern time. |
| 2026-02-27 | Merger completed, Avidity Biosciences became an indirect wholly owned subsidiary of Novartis AG; Current Report on Form 8-K filed. |
| 2026-03-02 | Company Common Stock will be suspended from trading on Nasdaq. |
Keywords
Avidity Biosciences, Novartis AG, Merger, Acquisition, Spin-off, Atrium Therapeutics, Delisting, Biotechnology, Pharmaceuticals, Rare Genetic Cardiomyopathies, AOC 1086, AOC 1072
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.